Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series
Frontiers in Immunology · 04.10.2024 · 15
DOI: 10.3389/fimmu.2024.1304792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 04.10.2024. Verfasst von Katrina A Williamson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Nod2 Signaling Adaptor Protein, Phenotype, Genotype. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The aim of this study was to characterize the phenotype and genotype of patients with Yao syndrome (YAOS), with focus on comparing to prior cohorts, identifying novel features, and describing treatment observations.
Methods
A retrospective medical records review of patients with YAOS seen at Mayo Clinic was conducted to characterize clinical features, NOD2 genotypes, and therapeutic trials and responses.
Results
Twenty-two patients diagnosed with YAOS were included. Eighteen patients (81.8%) were female and twenty (90.9%) were White. Mean age at symptom onset was 24.0 ± 14.8 years. Common clinical manifestations included fever (81.8% of patients), rash (95.5%), chronic gastrointestinal symptoms (100%), arthralgia/arthritis (95.5%), and sicca symptoms (68.2%). NOD2 genotypes as single variants included IVS8 + 158 in 14 patients (63.6%), R702W in 8 patients (36.4%), 1007fs in 4 (18.2%), and one patient had only a previously unreported rare variant. Eight patients (36.4%) had compound (two or more) NOD2 variants. Potential comorbidities of YAOS observed in this cohort included gastrointestinal dysmotility, autonomic dysfunction, and mast cell activation-like symptoms. Glucocorticoid responsiveness was observed in 15 of 20 patients exposed (75%). Eleven patients (50.0%) received IL-1 inhibitor therapy, and one patient (4.5%) received IL-6 inhibitor therapy with adequate disease control.
Conclusion
Our findings substantiate the occurrence of fevers, arthralgia/arthritis, rash, chronic gastrointestinal symptoms, and sicca-like symptoms described previously in patients with YAOS. Novel clinical features and one NOD2 variant not previously described were identified. Glucocorticoids, biologic IL-1 inhibitors, and IL-6 receptor inhibitors appeared to be effective for treatment of patients with YAOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Mayo Clinic, Rochester, MN, United States.
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, United States.
- Division of Pediatric Rheumatology, Mayo Clinic, Rochester, MN, United States.
- Division of Rheumatology, Mayo Clinic, Jacksonville, FL, United States.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.
Zitieren
APA
Williamson, K. A., Samec, M. J., Patel, J. A., Orandi, A. B., Wang, B., Crowson, C. S., Loftus, E. V., Alavi, A., Moyer, A. M., & Davis, J. M. (2024). Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1304792
Vancouver
Williamson KA, Samec MJ, Patel JA, Orandi AB, Wang B, Crowson CS, et al. Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1304792
BibTeX
@article{Williamson2024,
author = {Williamson, Katrina A and Samec, Matthew J and Patel, Jenny A and Orandi, Amir B and Wang, Benjamin and Crowson, Cynthia S and Loftus, Edward V and Alavi, Afsaneh and Moyer, Ann M and Davis, John M},
title = {Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series},
journal = {Frontiers in Immunology},
year = {2024},
volume = {15},
doi = {10.3389/fimmu.2024.1304792}
}
EUVIMED